16 December 2024NewsAmericasMarisa Woutersen

How Inhibrx defended a $450m damages suit

A Delaware jury unanimously sided with Sanofi-owned biotech Inhibrx, clearing it of trade secrets misappropriation claims. Amy Candido of Wilson Sonsini shares insights into the defence strategy that led to the win.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
22 May 2026   A US appeals court has handed the generic drugmaker victory in a closely watched dispute over a treatment for a serious inherited kidney condition, dealing a setback to its branded rival.
Americas
21 May 2026   European officials have again sided with Glenmark, concluding that the 3D mark for Boehringer’s HandiHaler device is ineligible for registration.
Americas
20 May 2026   The firm brings in a former VP at a biotech company, with biologics experience across antibodies, antibody drug-conjugates, peptides and gene and cell therapies.